The GH-IGF-1 axis in plain English
9 min read · Uplevel editorial
You've seen the phrase "GH levels" on clinic websites and in longevity content until it's become a kind of shorthand for youthfulness — the thing that goes down as you age and takes everything else with it. What that framing almost never explains is that "GH levels" is itself a misleading concept, because growth hormone doesn't really have a level in the way that testosterone or thyroid hormone does. GH is pulsatile. It's released in bursts. Most of the day, it's nearly undetectable in the bloodstream. And much of what gets attributed to GH — the tissue growth, the protein synthesis, the metabolic shifts, the cellular maintenance — isn't actually done by GH at all. It's done by a different hormone that GH triggers downstream. Understanding the actual architecture of this system is what makes every conversation about GH-related interventions either sensible or confused.
The story starts in the hypothalamus, a small structure at the base of the brain that functions as the interface between the nervous system and the endocrine system. Among its many jobs, the hypothalamus produces growth hormone-releasing hormone — GHRH — and a counterbalancing peptide called somatostatin. These two signals compete. GHRH travels through a specialized portal blood supply to the anterior pituitary, a small gland that hangs just below the hypothalamus, and binds to receptors on somatotroph cells — the cells in the pituitary whose primary job is making and releasing GH. The signal says: release. Somatostatin says: stop. The balance between these two signals at any given moment determines whether GH is released.
The pituitary responds to a favorable GHRH-to-somatostatin ratio by releasing growth hormone in a pulse. Not gradually. In a burst. The pulse enters systemic circulation, travels to peripheral tissues, and binds to GH receptors throughout the body. But here's the part that's underappreciated: GH itself is responsible for fewer of its attributed effects than most descriptions suggest. Many of the systemic effects that people associate with "GH" — lean mass maintenance, cellular growth, protein synthesis, bone density support — are not direct effects of GH. They're effects of IGF-1, a different hormone that GH triggers the liver to produce.
IGF-1 stands for insulin-like growth factor 1. When GH reaches the liver and binds to hepatic GH receptors, the liver synthesizes and secretes IGF-1 into circulation. IGF-1 then acts on virtually every tissue in the body: muscle cells respond by increasing protein synthesis and inhibiting protein breakdown. Bone cells respond by increasing growth and density. Fat cells respond with lipolysis — the breakdown of stored fat. Brain cells, connective tissue, and skin all respond to IGF-1 in tissue-specific ways. The range and consistency of these effects is why IGF-1 is sometimes described as the mediator of growth — the systemic messenger that carries the growth signal from the liver to everything else.
IGF-1 has additional sources beyond GH-stimulated hepatic production: various tissues produce it locally in response to mechanical stress, nutrition, and other signals. But circulating IGF-1, which is what blood tests measure, is primarily of hepatic origin and reflects the integrated GH signaling that the liver has received over the preceding days. This is why IGF-1 is a more useful biomarker for assessing GH-axis function than GH itself: a blood draw for GH is essentially a lottery — depending on whether you're drawing in the middle of a pulse or the trough between pulses, you could get wildly different numbers from the same person on the same day. IGF-1, produced continuously in response to the accumulated GH signal, is integrated over time and much more stable. It's the signal averaged across the noise.
The negative feedback loop completes the picture. As IGF-1 rises in circulation, it feeds back to both the hypothalamus and the pituitary to inhibit further GH release. It suppresses GHRH secretion at the hypothalamic level and directly suppresses somatotroph cells at the pituitary. GH itself also participates in negative feedback. The result is a self-regulating system: when the axis is working, GH pulses trigger IGF-1 production, which then turns down the next pulse. This is what keeps GH and IGF-1 within physiological ranges in healthy individuals, and it's the mechanism that distinguishes GHRH-based stimulation from exogenous GH injection — working through this regulated pathway means the feedback loop still operates.
The somatopause is what happens to this entire system with age. Starting in the thirties, and accelerating through the forties and fifties, the GH-IGF-1 axis gradually slows. GHRH output from the hypothalamus decreases. Pituitary responsiveness to GHRH declines. Somatostatin tone — the inhibitory signal — increases. The result is that GH pulses become smaller, less frequent, and occur predominantly during shorter and shallower slow-wave sleep episodes, which themselves are declining. The GH pulse that a thirty-year-old produces during the first deep-sleep cycle is substantially larger than what the same person produces at fifty. IGF-1 tracks this decline: serum IGF-1 in a healthy fifty-year-old is typically thirty to forty percent lower than in a healthy twenty-five-year-old.
The consequences of somatopause are real and widespread. Reduced lean mass maintenance — even with consistent resistance training, recovery and hypertrophic signaling become less efficient. Increased visceral fat accumulation, because GH's lipolytic effect on visceral adipose is one of the primary mechanisms that keeps it in check during early adulthood. Declining slow-wave sleep depth, in a bidirectional relationship: lower GH worsens sleep architecture, and worse sleep architecture further blunts GH release. Skin quality changes — collagen synthesis, which GH and IGF-1 both support, declines. The clinical descriptions of "feeling older" that don't map neatly onto specific diagnoses often overlap substantially with the downstream effects of a quieter GH-IGF-1 axis.
Where peptide interventions enter this picture depends on which part of the axis you're acting on. GHRH analogs — sermorelin, tesamorelin, CJC-1295 — intervene at the hypothalamic-to-pituitary step, amplifying the signal that tells the pituitary to release GH. The pituitary response produces a GH pulse, which reaches the liver, which produces IGF-1. The intervention is upstream and operates through the regulated pathway. GHRP-class compounds — Ipamorelin, GHRP-2, GHRP-6, Hexarelin — intervene at the pituitary through the ghrelin receptor, a different pathway that also produces GH release, also regulated by the same feedback loop. MK-677, the oral ghrelin mimetic, acts through the same GHS-R1a receptor with sustained rather than pulsatile activation. Exogenous IGF-1 injection — used in some research and clinical contexts for growth disorders — intervenes at the far end of the pathway, after the liver step, bypassing the pituitary entirely and delivering the downstream mediator directly.
Each entry point has different characteristics. Upstream interventions preserve the feedback architecture. Downstream interventions bypass it. The location on the axis matters for side-effect profiles, for receptor desensitization dynamics, and for what biological question you're actually trying to answer.
One thing the axis map makes clear is why "checking your IGF-1" is more informative than checking a random GH level, and why neither single measurement fully characterizes axis function. A thorough assessment — IGF-1 level in context of age-specific reference ranges, GHRH stimulation testing if GH deficiency is suspected, consideration of overnight GH secretion patterns — gives a more complete picture of where the axis is operating. A provider working in this space should be starting with that picture before choosing any intervention, because the location of the problem on the axis should influence the choice of where to intervene on it.
The GH-IGF-1 axis doesn't exist in isolation from the rest of endocrine physiology. Thyroid hormone status modulates GH response — hypothyroidism blunts GH release. Estrogen and testosterone have complex interactions with GH secretion and IGF-1 bioavailability. Nutritional status matters profoundly: fasting raises GH but lowers IGF-1; overfeeding raises IGF-1 but can suppress GH pulse amplitude. Chronic sleep restriction suppresses GH secretion through the slow-wave sleep dependency described above. Understanding the axis means understanding it as embedded in the broader metabolic and hormonal context — not as a separate dial to be turned independently of everything else.
The conversation about GH-related interventions, when it's grounded in how this system actually works, looks quite different from the mythology around it. It's not about maximizing GH. It's about understanding where the axis has slowed, why it has slowed, and which point of intervention is most likely to restore function within the regulatory framework that keeps the system operating safely. That's a clinical conversation — not a supplement protocol.
Frequently asked